El interés en corto de Bionomics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Bionomics. Los datos de interés en corto se actualizan cada dos semanas.

Bionomics (NASDAQ:BNOX) Bolsa, Informe de interés en corto

Bionomics

Bionomics Ltd is a global, clinical-stage biopharmaceutical company. It is primarily engaged in the development of therapeutics for diseases of the central nervous system and cancer. The company's reportable segment is the Drug Discovery and Development segment which is engaged in the discovery, development, and commercialization of compounds to match a target product profile. The company generates all of its revenues from Australia.

Bionomics Limited - American Depository Shares

Bionomics Ltd

WIIM

Freeport-McMoRan shares are trading lower after Scotiabank downgraded the stock from Sector Outperform to Sector Perform and announced a $52 price target. Also, the company announced it may delay its copper production at the Manyar Smelter in Indonesia.

News

White House Says It Is Not Considering Using Taft-Hartley Act To Prevent Port Workers Strike

White House, Asked About Possible Port Workers Union Strike Says We Encourage All Parties To Come To Table And Negotiate

Royal Caribbean Cruises Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>) shares are trading lower by 2.2% to $173.60 during Monday&#8217;s session. Shares of cruise stocks are trading lower in sympathy with Carnival Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>), which issued guidance <a href="https://www.benzinga.com/news/earnings/24/09/41095980/carnival-q3-earnings-15-topline-growth-record-operating-income-guidance-boost-and-more">below estimates</a>.
What Happened: Royal Caribbean saw its stock decline on Monday following the release of Carnival&#8217;s third-quarter earnings, despite Carnival reporting better-than-expected results. 
Carnival&#8217;s earnings report highlighted a strong quarter, with adjusted earnings per share of $1.27, surpassing analyst expectations of $1.16, and quarterly sales of $7.90 billion, up 15.2% year-over-year. 
Despite these positive figures, the market's focus shifted to Carnival's weaker-than-expected fourth-quarter guidance, which raised concerns about the broader cruise industry, leading to declines in Royal Caribbean&#8217;s stock.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41100587/s-p-500-etf-titans-drive-691b-in-2024-inflows-nasdaq-bitcoin-etfs-close-behind">S&amp;P 500 ETF Titans Drive $691B In 2024 Inflows: Nasdaq, Bitcoin ETFs Close Behind</a>
Royal Caribbean, as one of the largest cruise operators in the world, often moves in tandem with its major competitors like Carnival. With Carnival projecting fourth-quarter adjusted earnings per share of just 5 cents—significantly below analyst estimates of $1.16—investors became wary of broader industry challenges heading into the traditionally slower winter season. 
Carnival's cautious outlook for the coming quarter, despite solid bookings and liquidity, suggests that the cruise industry may face lingering pressures, including rising operating costs, fuel price volatility, and economic uncertainty that could weigh on profitability.
What Else: Royal Caribbean has been riding a wave of post-pandemic recovery, with demand for cruises rebounding sharply as consumers sought leisure travel after years of restrictions. The company, known for its luxury and innovative cruise offerings, such as the world's largest cruise ship, Icon of the Seas, has seen strong bookings and record demand for 2024 sailings. 
However, the news from Carnival indicated that despite high occupancy levels and solid forward bookings, near-term earnings could be pressured by rising expenses, such as fuel costs and inflationary pressures on labor and supply chains.
Royal Caribbean&#8217;s stock has benefited from a booming travel industry, with many analysts expecting continued strength in consumer demand for cruises. However, the lower-than-expected earnings guidance from Carnival cast a shadow over these expectations, prompting fears that Royal Caribbean may also face margin compression in the final quarter of 2024. 
Investors appear to be anticipating that similar cost challenges could affect Royal Caribbean&#8217;s upcoming earnings, given that both companies operate in the same competitive and cost-sensitive industry.
Read Also: <a href="https://www.benzinga.com/markets/equities/24/09/41097541/amazon-apple-tesla-brace-for-supply-chain-disruptions-as-potential-east-coast-dockworkers-strike">Amazon, Apple, Tesla Brace For Supply Chain Disruptions As Potential East Coast Dockworkers Strike Nears</a>
<h2 class="wp-block-heading">How To Buy RCL Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Royal Caribbean Group&#8217;s case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, RCL has a 52-week high of $184.41 and a 52-week low of $78.35.

Why Royal Caribbean Cruises (RCL) Shares Are Falling

Tesla CEO Elon Musk has long been vocal about his views on U.S. immigration policy, advocating for increased legal immigration while calling for tougher enforcement against illegal crossings. 
During a September 2023 visit to the U.S.-Mexico border, Musk underscored his stance, arguing that America should welcome hardworking immigrants but must also uphold the law. This complex view on immigration, shaped by his own experiences as an immigrant, has sparked significant attention.
An often-overlooked chapter of Musk's life involves his early years in the U.S. when he and his brother, Kimbal Musk, were building their first startup, Zip2.
Also Read: <a href="https://www.benzinga.com/general/entertainment/24/09/41084606/elon-musk-targets-lopsided-anti-trump-donations-by-netflix-employees-as-cancellations-soare">Elon Musk Targets &#8216;Lopsided&#8217; Anti-Trump Donations By Netflix Employees As Cancellations Soared After Co-Founder Reed Hastings Donated To Kamala Harris</a>
What Happened: In a 2013 Milken Institute event, Kimbal Musk openly shared that both he and Elon were &#8220;illegal immigrants&#8221; during the launch of Zip2 — their first U.S.-based company, <a href="https://www.cnn.com/2024/09/29/us/elon-musk-immigration-gray-area-cec/index.html">CNN </a>reports. 
Elon Musk interjected, calling the situation a &#8220;gray area.&#8221; Still, the anecdote highlights a less-discussed chapter in his personal immigration journey.
It is unclear what kind of visas they had at the time.
According to CNN, investors helped the Musk brothers secure legal status shortly after funding arrived.
More recently, Elon Musk aligned his views with those of JPMorgan Chase CEO Jamie Dimon, who warned that failure to control the border would &#8220;destroy our country.&#8221; Musk echoed Dimon's sentiments on X, agreeing that border control is <a href="https://www.benzinga.com/news/24/09/41017982/elon-musk-agrees-with-jamie-dimon-if-you-do-not-control-the-borders-you-are-going-to-destroy-our-cou">critical to national security.</a>
Why It Matters: Elon Musk's personal immigration story, particularly the details shared by his brother, adds complexity to his vocal stance on immigration reform. His calls for stricter enforcement of U.S. immigration laws, juxtaposed with the challenges he faced as an immigrant entrepreneur, reflect the broader challenges many face within the current system.
 This background also resonates with voters, as immigration remains a key issue heading into the 2024 presidential election.
Musk's influence, especially through his platform X, continues to drive significant public discourse around the need for legal immigration reforms while addressing illegal immigration concerns. His agreement with Dimon on border security amplifies the debate, positioning Musk as a central figure in this conversation. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41083814/mark-cuban-warns-elon-musk-that-when-the-time-comes-he-needs-trump-the-most-he-will-find-out-the-tru">Mark Cuban Warns Elon Musk That When The Time Comes He Needs Trump The Most He Will Find Out The Truth: &#8216;His Loyalty Is Only To Himself&#8217;</a></li>
</ul>
Photo: Shutterstock

General

Elon Musk's Brother Once Said They Were 'Illegal Immigrants' During Startup's Early Days

Advance Auto Parts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AAP#NYSE">AAP</a>) shares are trading lower by 5.3% to $39.20 during Monday&#8217;s session. Shares of auto supplier stocks may be under pressure following <a href="https://www.benzinga.com/markets/equities/24/09/41089577/whats-going-on-with-stellantis-stock-monday">weak guidance</a> from Stellantis, which could be causing concern for the sector.
What Happened: Shares of Advance Auto Parts fell sharply Monday, following the announcement from Stellantis NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) that the global automaker revised its fiscal 2024 guidance.
The Stellantis report, which sent shockwaves across the auto sector, also led to declines in other major automakers like General Motors Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>), with market concerns growing over weakened auto sales, supply chain constraints, and profitability.
Read Also: <a href="https://www.benzinga.com/etfs/sector-etfs/24/09/41098327/longshoremen-strike-looms-standoff-could-cost-1b-a-day-leave-thanksgiving-prep-in-a-pinch">Longshoremen Strike Looms, Standoff Could Cost $1B A Day, Leave Thanksgiving Prep In A Pinch</a>
Stellantis, the parent company of brands like Chrysler, Dodge and Jeep, cut its adjusted operating margin expectations to a range of 5.5%-7.0%, down from its prior double-digit growth targets. The company also projected negative industrial free cash flow for fiscal 2024, between -€5 billion to -€10 billion, a stark contrast to previous expectations of positive cash flow. 
These financial adjustments are attributed to substantial shipment declines in North America, increased incentives on aging vehicle inventories, and overall deterioration in global market conditions, which many analysts believe could signal broader challenges for the automotive and aftermarket parts industries.
What Else: Advance Auto Parts, a leading provider of aftermarket automotive parts, is particularly sensitive to fluctuations in the broader automotive sector. While the company primarily caters to the DIY market and professional repair shops, any slowdown in new car sales and production impacts the demand for aftermarket parts. 
Stellantis' announcement of declining shipments — now expected to reduce by over 200,000 vehicles in the second half of 2024 — suggests fewer cars on the road and in need of parts over the near term. 
Additionally, the increased incentives to push older model-year vehicles could mean reduced profitability for automakers, which often translates into leaner inventory and less need for replenishment in parts.
Read Also: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/09/41100587/s-p-500-etf-titans-drive-691b-in-2024-inflows-nasdaq-bitcoin-etfs-close-behind">S&amp;P 500 ETF Titans Drive $691B In 2024 Inflows: Nasdaq, Bitcoin ETFs Close Behind</a>
<h2 class="wp-block-heading">Is AAP A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/AAP">Advance Auto Parts</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Advance Auto Parts does pay a dividend, which yields 1.64% per year as of the closing price on Sep. 30, 2024. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 8.89%, you'll need to buy a share of Allspring Inc Opps by the Oct. 15, 2024. Once done, you can expect to receive a nominal payout of $0.05 on Nov. 1, 2024.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/AAP">Advance Auto Parts</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, AAP has a 52-week high of $88.56 and a 52-week low of $37.51.

STLA

Why Advance Auto Parts (AAP) Stock Is Trading Lower

Deep-pocketed investors have adopted a bullish approach towards First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in FSLR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 36 extraordinary options activities for First Solar. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 58% leaning bullish and 33% bearish. Among these notable options, 12 are puts, totaling $701,960, and 24 are calls, amounting to $2,315,304.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $120.0 to $310.0 for First Solar during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for First Solar's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across First Solar's significant trades, within a strike price range of $120.0 to $310.0, over the past month.
<h3>First Solar Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727723732_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$23.0</td>
<td>$22.6</td>
<td>$22.6</td>
<td>$270.00</td>
<td>$1.0M</td>
<td style="text-align: right;">234</td>
<td style="text-align: right;">453</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$28.95</td>
<td>$28.7</td>
<td>$28.95</td>
<td>$280.00</td>
<td>$133.1K</td>
<td style="text-align: right;">438</td>
<td style="text-align: right;">46</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$153.95</td>
<td>$152.0</td>
<td>$153.9</td>
<td>$120.00</td>
<td>$123.2K</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">8</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$45.5</td>
<td>$45.3</td>
<td>$45.3</td>
<td>$280.00</td>
<td>$117.7K</td>
<td style="text-align: right;">123</td>
<td style="text-align: right;">26</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>10/18/24</td>
<td>$10.55</td>
<td>$10.35</td>
<td>$10.48</td>
<td>$250.00</td>
<td>$111.9K</td>
<td style="text-align: right;">737</td>
<td style="text-align: right;">155</td>
</tr>
</tbody>
</table>

<h3>About First Solar</h3>
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.
Following our analysis of the options activities associated with First Solar, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of First Solar</h3>
<ul>
<li>Currently trading with a volume of 895,483, the FSLR's price is down by -2.56%, now at $249.2. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 29 days.</li>
</ul>
<h3>Professional Analyst Ratings for First Solar</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $321.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Truist Securities downgraded its action to Buy with a price target of $300. 
&#x2A; An analyst from B of A Securities persists with their Buy rating on First Solar, maintaining a target price of $343. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for First Solar, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

FSLR

A Closer Look at First Solar's Options Market Dynamics

Deep-pocketed investors have adopted a bullish approach towards Lowe's Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LOW usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 21 extraordinary options activities for Lowe's Companies. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 42% leaning bullish and 23% bearish. Among these notable options, 7 are puts, totaling $283,740, and 14 are calls, amounting to $1,548,705.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $240.0 to $300.0 for Lowe's Companies over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Lowe's Companies's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Lowe's Companies's whale trades within a strike price range from $240.0 to $300.0 in the last 30 days. 
<h3>Lowe's Companies Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727723727_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.9</td>
<td>$20.8</td>
<td>$20.8</td>
<td>$270.00</td>
<td>$424.2K</td>
<td style="text-align: right;">51</td>
<td style="text-align: right;">486</td>
</tr>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$20.75</td>
<td>$20.7</td>
<td>$20.7</td>
<td>$270.00</td>
<td>$335.3K</td>
<td style="text-align: right;">51</td>
<td style="text-align: right;">852</td>
</tr>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$20.8</td>
<td>$20.7</td>
<td>$20.7</td>
<td>$270.00</td>
<td>$134.5K</td>
<td style="text-align: right;">51</td>
<td style="text-align: right;">486</td>
</tr>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$20.95</td>
<td>$20.4</td>
<td>$20.7</td>
<td>$270.00</td>
<td>$124.2K</td>
<td style="text-align: right;">51</td>
<td style="text-align: right;">179</td>
</tr>
<tr>
<td>LOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$20.9</td>
<td>$20.4</td>
<td>$20.7</td>
<td>$270.00</td>
<td>$105.5K</td>
<td style="text-align: right;">51</td>
<td style="text-align: right;">290</td>
</tr>
</tbody>
</table>

<h3>About Lowe's Companies</h3>
Lowe's is the second-largest home improvement retailer in the world, operating more than 1,700 stores in the United States, after the 2023 divestiture of its Canadian locations (RONA, Lowe's Canada, Réno-Dépôt, and Dick's Lumber). The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a high-single-digit share of the domestic home improvement market, based on US Census data and management's market size estimates.
Following our analysis of the options activities associated with Lowe's Companies, we pivot to a closer look at the company's own performance.
<h3>Lowe's Companies's Current Market Status</h3>
<ul>
<li>With a trading volume of 913,772, the price of LOW is up by 0.61%, reaching $268.77.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 50 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Lowe's Companies</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $291.75.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Melius Research downgraded its action to Buy with a price target of $290. 
&#x2A; An analyst from TD Cowen persists with their Hold rating on Lowe's Companies, maintaining a target price of $265. 
&#x2A; An analyst from Oppenheimer has elevated its stance to Outperform, setting a new price target at $305. 
&#x2A; An analyst from Piper Sandler has decided to maintain their Overweight rating on Lowe's Companies, which currently sits at a price target of $307. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Lowe's Companies options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Market Whales and Their Recent Bets on LOW Options

Whales with a lot of money to spend have taken a noticeably bearish stance on JPMorgan Chase.
Looking at options history for JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) we detected 60 trades.
If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 43 are puts, for a total amount of $2,869,780 and 17, calls, for a total amount of $1,617,064.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $155.0 to $225.0 for JPMorgan Chase over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for JPMorgan Chase's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of JPMorgan Chase's whale activity within a strike price range from $155.0 to $225.0 in the last 30 days. 
<h3>JPMorgan Chase 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727723722_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.5</td>
<td>$2.45</td>
<td>$2.46</td>
<td>$225.00</td>
<td>$492.0K</td>
<td>13.8K</td>
<td>2.2K</td>
</tr>
<tr>
<td>JPM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$3.85</td>
<td>$3.75</td>
<td>$3.8</td>
<td>$180.00</td>
<td>$380.0K</td>
<td>2.3K</td>
<td>1.0K</td>
</tr>
<tr>
<td>JPM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.3</td>
<td>$200.00</td>
<td>$215.0K</td>
<td>4.0K</td>
<td>543</td>
</tr>
<tr>
<td>JPM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$12.6</td>
<td>$12.4</td>
<td>$12.4</td>
<td>$200.00</td>
<td>$186.0K</td>
<td>753</td>
<td>150</td>
</tr>
<tr>
<td>JPM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$56.7</td>
<td>$56.7</td>
<td>$56.7</td>
<td>$160.00</td>
<td>$119.0K</td>
<td>871</td>
<td>21</td>
</tr>
</tbody>
</table>

<h3>About JPMorgan Chase</h3>
JPMorgan Chase is one of the largest and most complex financial institutions in the United States, with nearly $4.1 trillion in assets. It is organized into four major segments--consumer and community banking, corporate and investment banking, commercial banking, and asset and wealth management. JPMorgan operates, and is subject to regulation, in multiple countries.
Having examined the options trading patterns of JPMorgan Chase, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of JPMorgan Chase</h3>
<ul>
<li>With a volume of 4,170,048, the price of JPM is down -0.59% at $209.25. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 11 days.</li>
</ul>
<h3>Expert Opinions on JPMorgan Chase</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $227.5.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Deutsche Bank downgraded its action to Hold with a price target of $235. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on JPMorgan Chase, maintaining a target price of $220. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for JPMorgan Chase with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

JPMorgan Chase Options Trading: A Deep Dive into Market Sentiment

Shares of General Motors Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) and Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) are experiencing declines amid broad weakness in the auto sector following Stellantis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) <a href="https://www.benzinga.com/markets/equities/24/09/41089577/whats-going-on-with-stellantis-stock-monday">lowering its full-year 2024 guidance.</a>
What To Know: Stellantis has revised its adjusted operating margin expectations to a range of 5.5%–7.0%, a drop from the double-digit growth previously forecasted. Additionally, the company now anticipates industrial free cash flow for fiscal 2024 to fall between negative €5 billion and negative €10 billion, reversing its earlier positive outlook.
This revision comes as Stellantis faces challenges with North American performance and broader global industry deterioration. The automaker is taking several remedial steps, including cutting North American shipments by over 200,000 vehicles in the second half of 2024—double the previous guidance of 100,000—while increasing incentives on older model-year vehicles to stimulate demand. These actions follow the company's earlier report of a 14% revenue decline in the first half of 2024, with net profit dropping by 48%.
GM And F Price Action: General Motors shares were down by 2.61% at $44.80 and Ford shares were down by 2.41% at $10.52 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
Image via Unsplash.

Why Are General Motors And Ford Shares Trading Lower Today

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor&#39;s dream. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.
Cash flow can come from bond interest, interest from other types of investments, and of course, dividends. A dividend is that coveted distribution of a company&#39;s earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends account for significant portions of long-term returns, with dividend contributions exceeding one-third of total returns in many cases.
<h2>Unitil in Focus</h2>
Headquartered in Hampton, Unitil (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/utl#NYSE">UTL</a>) is a Utilities stock that has seen a price change of 13.54% so far this year. The utility is paying out a dividend of $0.43 per share at the moment, with a dividend yield of 2.85% compared to the Utility - Electric Power industry&#39;s yield of 3.24% and the S&amp;P 500&#39;s yield of 1.52%.
Taking a look at the company&#39;s dividend growth, its current annualized dividend of $1.70 is up 4.9% from last year. In the past five-year period, Unitil has increased its dividend 5 times on a year-over-year basis for an average annual increase of 2.77%. Any future dividend growth will depend on both earnings growth and the company&#39;s payout ratio; a payout ratio is the proportion of a firm&#39;s annual earnings per share that it pays out as a dividend. Unitil&#39;s current payout ratio is 56%. This means it paid out 56% of its trailing 12-month EPS as dividend.
Looking at this fiscal year, UTL expects solid earnings growth. The Zacks Consensus Estimate for 2024 is $2.92 per share, representing a year-over-year earnings growth rate of 3.55%.
<h2>Bottom Line</h2>
Investors like dividends for many reasons; they greatly improve stock investing profits, decrease overall portfolio risk, and carry tax advantages, among others. It&#39;s important to keep in mind that not all companies provide a quarterly payout.
High-growth firms or tech start-ups, for example, rarely provide their shareholders a dividend, while larger, more established companies that have more secure profits are often seen as the best dividend options. Income investors have to be mindful of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, UTL is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of 3 (Hold).
<a href="https://www.zacks.com/stock/news/2343529/why-unitil-utl-is-a-great-dividend-stock-right-now?cid=CS-BENZ-FT-tale_of_the_tape|yseop_template_5-2343529">To read this article on Zacks.com click here.</a>

Dividends

Small Cap

Trading Ideas

Why Unitil Is A Great Dividend Stock Right Now

Stocks slid Monday after Federal Reserve Chairman Jerome Powell said that future interest rate cuts would depend on economic data during his appearance at the National Association of Business Economics. While Powell noted inflation is moving closer to the Fed&#8217;s 2% target and highlighted positive economic progress, his comments on data-driven rate decisions added uncertainty to the market just weeks after <a href="https://www.benzinga.com/news/24/09/41068393/inflation-decline-strengthens-confidence-in-feds-interest-rate-cut-if-you-were-second-guessing-the-f">a recent rate cut.</a>
What Happened: Powell appeared at the National Association of Business Economics (NABE) in Nashville, Tennessee, where <a href="https://www.benzinga.com/news/24/09/41085958/fed-chair-jerome-powell-set-to-speak-as-economists-raise-concerns-over-risks-arising-from-potential">he gave prepared remarks</a> and took part in a fireside conversation sharing details on the recent interest rate cut, inflation, the housing market and what's next for the Fed in November.
"Our economy is strong overall and has made progress," Powell said.
Powell said "inflation has eased" and "labor market conditions are solid."
The Fed Chairman said inflation is on a sustainable path back to 2%, and the recent 50-basis point rate cut shows growing confidence in the goal.
"Our focus was on bringing down inflation."
Powell said the Fed's patient approach to rate cuts "has paid dividends."
Speaking on the labor market, Powell said the strength of the labor market "can be maintained" and that unemployment rates are well within estimates.
"Over the past year, we have continued to see solid growth and healthy gains in the labor force and in productivity."
Powell said one of the Fed's main goals is not to have higher unemployment, as they bring inflation down.
"We have made a good deal of progress."
Read Also: <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/09/40928301/interest-rates-in-free-fall-what-it-means-for-mortgages-credit-cards-and-your-wallet-a">Interest Rates In Free-Fall: What It Means For Mortgages, Credit Cards And Your Wallet As The Federal Reserve Springs Into Action For First Time In 4 Years</a>
What's Next: Powell said the Federal Reserve is not on a pre-set course to decide on further rate cuts at the November meeting.
"Overall, the economy is in solid shape. We intend to use our tools to keep it there," Powell said.
The Fed Chairman said decisions will be made on a meeting-by-meeting basis.
Powell said the goal is to see income and savings rates go up after it appears that consumers are spending more than their income.
For future interest rate cuts, Powell said the process will play out over time and does not need to happen fast.
"Will depend on the data."
Powell said the rate cuts can happen slower or faster depending on how the economy moves.
Ahead of the November meeting there will be several key pieces of data, which include reports on inflation and unemployment. Powell said the Fed will "take everything into account."
"Looking forward, if the economy evolves broadly as expected, policy will move over time toward a more neutral stance."
Market Reaction: The stock market dripped slightly, following Powell's comments. The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500, was trading around $571.12 at the time Powell began talking and is trading at $570.50 at the time of publication.
The Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) trades at $485.03 at the time of writing, down 0.35% on the day.
The SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) is down 0.44% to $421.08 at the time of publication Monday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/education/24/09/41031059/after-fed-rate-cuts-is-tesla-nvidia-apple-or-amazon-the-best-investment-poll-reveals-top-magnif">After Fed Rate Cuts, Is Tesla, Nvidia, Apple, Or Amazon The Best Investment? Poll Reveals Top Magnificent 7 Stock</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Econ #s

Federal Reserve

SPDR Dow Jones Industrial Average ETF Trust

Powell Says Future Interest Rate Cuts Hinge On Data, Stocks Slip: 'Economy Is In Solid Shape, We Intend To Use Our Tools To Keep It There'

In a speech at Token2049, Edward Snowden, the former NSA contractor turned whistleblower, addressed the evolving landscape of digital privacy, government control and the <a href="https://www.benzinga.com/markets/cryptocurrency/24/05/38616885/bitcoins-clock-is-ticking-why-edward-snowden-issues-final-warning">role of cryptocurrency</a> in shaping a new world order.
What Happened: Pointing on how government is exerting control over digital platforms, Snowden cited the <a href="https://www.benzinga.com/news/24/09/40893281/telegram-ceo-pavel-durov-faces-10-year-sentence-and-500k-fine-in-frances-first-cybercrime-case-under">recent case of Telegram&#8217;s founder Pavel Durov.</a> He <a href="https://www.youtube.com/watch?v=XD-XU6Y3TfA">stated,</a> "We saw a well-coordinated effort by the old powers to gain control over Telegram by taking its founder Durov as frankly a hostage in France."
The whistleblower emphasized the importance of designing systems that resist state interference, praising Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and other cryptocurrencies for their approach. He argued, &#8220;You have to design your app so that there will never be a head that the state can point a gun at, or they will do it."
Snowden expressed concern about the increasing attempts by governments to control digital communication, mentioning the European Union's chat control proposal. He warned, &#8220;They're laying the procedural framework for the global control the voices of every volume and that&#8217;s what it&#8217;s really about.&#8221;
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41011761/former-coinbase-cto-balaji-srinivasan-says-bitcoin-is-about-stopping-the-state-from-slowly">Former Coinbase CTO Balaji Srinivasan Says Bitcoin Is About Stopping The State From Slowly Draining Your Wealth</a>
Why It Matters: Addressing the crypto community, Snowden urged a focus on the core values of cryptocurrency, stating, "We need to talk about the ruling values of the system the crypto part of cryptocurrency that&#8217;s what makes it special." He cautioned against diluting these principles to appease institutional investors.
Snowden also touched on the potential dangers of emerging technologies, including AI and consumer electronics. He stressed the importance of decentralization and privacy in these areas.
Snowden called for a return to the foundational principles of cryptocurrency, stating, "We should defy bureaucracy, we should reject modernity. Embrace tradition and you&#8217;ll save the world." 
What&#8217;s Next: The influence of <a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a> is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/09/41009065/bitwise-cio-matt-hougan-the-most-powerful-people-in-finance-are-allocating-to-crypto">Bitwise CIO Matt Hougan: &#8216;The Most Powerful People In Finance Are Allocating To Crypto&#8217;</a></li>
</ul>
Image: Flickr

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Edward Snowden Cautions Crypto Industry Not To Dilute Principles: 'We Should Defy Bureaucracy'

MUFG

SMFG

Shares of Japanese banking companies are trading higher amid a rise in the price of the yen. Incoming Prime Minister Shigeru Ishiba announced plans for a snap election on October 27, shortly after his recent election victory.

Over the past 24 hours, Internet Computer's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">ICP</a>) price has fallen 5.87% to $9.1. This is opposite to its positive trend over the past week where it has experienced a 5.0% gain, moving from $8.7 to its current price. 
The chart below compares the price movement and volatility for Internet Computer over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1727723021_0.png" alt="price_chart" />
The trading volume for the coin has risen 12.0% over the past week diverging from the circulating supply of the coin, which has decreased 0.03%. This brings the circulating supply to 471.58 million. According to our data, the current market cap ranking for ICP is #28 at $4.30 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1727723021_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

$ICP

Cryptocurrency Internet Computer Down More Than 5% Within 24 hours

Over the past 24 hours, Wrapped Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WBTC</a>) price has fallen 3.78% to $63,179.00. This is opposite to its positive trend over the past week where it has experienced a 1.0% gain, moving from $63,204.70 to its current price. 
The chart below compares the price movement and volatility for Wrapped Bitcoin over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1727722952_0.png" alt="price_chart" />
The trading volume for the coin has decreased 19.0% over the past week, while the overall circulating supply of the coin has decreased 0.17% to over 152 thousand. This puts its current circulating supply at an estimated 100.0% of its max supply, which is 152 thousand. The current market cap ranking for WBTC is #16 at $9.67 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1727722952_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$WBTC

Wrapped Bitcoin Decreases More Than 3% Within 24 hours

Over the past 24 hours, Polkadot's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/dot/usd">DOT</a>) price has fallen 5.72% to $4.53. This is opposite to its positive trend over the past week where it has experienced a 3.0% gain, moving from $4.42 to its current price. 
The chart below compares the price movement and volatility for Polkadot over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1727722943_0.png" alt="price_chart" />
Polkadot's trading volume has climbed 12.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has increased 0.07%. This brings the circulating supply to 1.42 billion. According to our data, the current market cap ranking for DOT is #20 at $6.43 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1727722943_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$DOT

Polkadot Down More Than 5% Within 24 hours

Stellantis Recalling 190,000 Plug-in Hybrid Jeep Wrangler, Grand Cherokee Vehicles For Fire Risks

Truist Securities raised the price target for Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) and cites continued momentum in Korlym sales more than a decade after launch amid increasing competition and says it &#8220;is impressive and difficult to ignore.&#8221;
Korlym (mifepristone) is a prescription medicine used to treat high blood sugar (hyperglycemia) caused by high cortisol levels in the blood (hypercortisolism) in adults with endogenous Cushing syndrome who have type 2 diabetes mellitus or glucose intolerance and who cannot have surgery or for whom surgery has failed.&nbsp;
Cushing syndrome is&nbsp;a hormonal disorder that occurs when the body has too much cortisol, a hormone that helps the body respond to stress.&nbsp;
Truist analyst notes approximately 20K Cushing&#8217;s disease (pituitary adenoma) patients in the U.S., of which ~10K are adequately managed with surgical resection of the pituitary adenoma.
Medical management is recommended for the remaining 10K. Therefore, there&#8217;s still significant room for growth, with just ~2,000 hypercortisolism patients currently on Korlym.
In June, Teva Pharmaceuticals Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) reportedly sued Corcept Therapeutics, accusing it of a monopoly on Korlym.
The lawsuit, filed in federal court in San Francisco, alleges that Corcept and its sole distributor, Optime Care, engaged in anti-competitive practices <a target="_blank" href="https://www.benzinga.com/24/06/39339275/concerpt-therapeutics-shares-are-trading-lower-what-you-need-to-know" rel="noreferrer noopener">to stifle competition</a>.
In May,&nbsp;Corcept Therapeutics announced that the GRACE Phase 3 trial of&nbsp;relacorilant&nbsp;in patients with hypercortisolism (Cushing&#8217;s syndrome)&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/39039282/why-mid-cap-corcept-therapeutics-stock-trading-higher-on-tuesday" rel="noreferrer noopener">met its primary endpoint</a>.
The company is conducting a Phase 3 GRADIENT trial for relacorilant with enrolled adrenal adenoma patients to strengthen the case for treating patients whose hypercortisolism was driven by adrenal adenoma.
Data from GRACE and GRADIENT studies will form a part of the FDA application submission. The analyst says, &#8220;GRADIENT is well-powered for success.&#8221;
Truist notes that Corcept Therapeutics can achieve around $3 billion in total revenue within five years.
The analyst highlights that management emphasized that once relacorilant is approved, almost all existing patients on Korlym would be converted to relacorilant.
With increased market penetration of relacorilant in Cushing&#8217;s from 16% to 25% in 2033, Truist raised the price target from $65 to $76, <a target="_blank" href="https://www.benzinga.com/quote/CORT/analyst-ratings" rel="noreferrer noopener">with a Buy rating</a>.
Price Action: CORT stock is up 5.19% at $46.21 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41101457/optimism-around-aquestive-as-it-moves-forward-with-severe-allergy-baldness-candidat" target="_blank" rel="noreferrer noopener">Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate</a>.</li>
</ul>

Analyst Color

Price Target

Reiteration

Analyst Ratings

CORT

TEVA

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast

In the preceding three months, 7 analysts have released ratings for Inspire Medical Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INSP#NYSE">INSP</a>), presenting a wide array of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $222.86, along with a high estimate of $260.00 and a low estimate of $197.00. This current average represents a 6.7% decrease from the previous average price target of $238.86. 
<img src="https://www.benzinga.com/files/images/story/2024/1727722878_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Inspire Medical Systems among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$240.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$197.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Brett Fishbin</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$236.00</td>
<td>$278.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$260.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Mike Polark</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$200.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$217.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Kallum Titchmarsh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$250.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Inspire Medical Systems. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Inspire Medical Systems compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Inspire Medical Systems's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Inspire Medical Systems's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/INSP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Inspire Medical Systems analyst ratings.</a>
<h2>About Inspire Medical Systems</h2>
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
<h3>Understanding the Numbers: Inspire Medical Systems's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Inspire Medical Systems's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 29.65% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Inspire Medical Systems's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 5.0%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.6%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Inspire Medical Systems's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.38% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Inspire Medical Systems's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INSP

Analyst Scoreboard: 7 Ratings For Inspire Medical Systems

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Bionomics (BNOX – Research Report), with a price targe...

Bionomics's BNC210 Shows Promise for PTSD Treatment: A Buy Rating Analysis

Maxim Group analyst Jason McCarthy has maintained their bullish stance on BNOX stock, giving a Buy rating on March 21. Jason McCarthy has given his...

Buy Rating Affirmed for Bionomics' BNC210 Following Promising PTSD Study Results

Bionomics (BNOX) has released an update. Bionomics Limited, an Australian biotech firm, has entered into a Securities Purchase Agreement with selec...

Bionomics Secures Growth Through Strategic Sale

Bionomics Secures Solid Financial Runway with $70M Financing Ahead of Phase 3 SAD Study, Earns 'Buy' Rating

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into this morning and we have all of the hottest news worth checking out on Thursday!



Moving stocks this morning are an acquisition deal, a clinical trial launch, earnings reports and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Chuy&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/chuy-stock-quote/">CHUY</a>) stock is rocketing more than 46% on a <a href="https://www.nasdaq.com/press-release/darden-restaurants-acquire-chuys-holdings-inc-approximately-605-million-transaction">$605 million acquisition deal</a>.</li>



<li>Onconetix (NASDAQ:<a href="https://investorplace.com/stock-quotes/onco-stock-quote/">ONCO</a>) shares are soaring over 43% alongside heavy pre-market trading.</li>



<li>Apollomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/aplm-stock-quote/">APLM</a>) stock is surging more than 25% with strong early morning trading.</li>



<li>Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) shares are rising over 23% as it <a href="https://www.nasdaq.com/press-release/bionomics-initiates-affirm-1-phase-3-clinical-trial-bnc210-social-anxiety-disorder">kicks off a Phase 3 clinical trial</a>.</li>



<li>Big Tree Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/dsy-stock-quote/">DSY</a>) stock is increasing more than 18% with strong pre-market trading.</li>



<li>ZimVie (NASDAQ:<a href="https://investorplace.com/stock-quotes/zimv-stock-quote/">ZIMV</a>) shares are heading over 13% higher without any clear news on Thursday morning.</li>



<li>SAI.TECH Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/sai-stock-quote/">SAI</a>) stock is gaining more than 12% on a <a href="https://www.globenewswire.com/news-release/2024/07/18/2914992/0/en/SAI-TECH-Global-Corporation-Announces-Share-Repurchase-Program.html">share repurchase program</a>.</li>



<li>MultiMetaVerse (NASDAQ:<a href="https://investorplace.com/stock-quotes/mmv-stock-quote/">MMV</a>) shares are climbing over 11% as it continues a recent rally.</li>



<li>Psyence Biomedical (NASDAQ:<a href="https://investorplace.com/stock-quotes/pbm-stock-quote/">PBM</a>) stock is jumping more than 10% despite a lack of news today.</li>



<li>XWELL (NASDAQ:<a href="https://investorplace.com/stock-quotes/xwel-stock-quote/">XWEL</a>) shares are up over 10% this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Leslies (NASDAQ:<a href="https://investorplace.com/stock-quotes/lesl-stock-quote/">LESL</a>) stock is diving more than 21% on <a href="https://www.nasdaq.com/press-release/leslies-inc-announces-preliminary-third-quarter-fiscal-2024-financial-results-and">preliminary earnings and guidance</a>.</li>



<li>Aptevo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/apvo-stock-quote/">APVO</a>) shares are rumbling over 13% after a massive rally yesterday.</li>



<li>Domino&rsquo;s Pizza (NYSE:<a href="https://investorplace.com/stock-quotes/dpz-stock-quote/">DPZ</a>) stock is sliding more than 13% with the release of its <a href="https://ir.dominos.com/static-files/68ecdbfc-bd1c-486a-a574-d6f54b7e5132">Q2 earnings report</a>.</li>



<li>CBL International (NASDAQ:<a href="https://investorplace.com/stock-quotes/banl-stock-quote/">BANL</a>) shares are taking an over 12% beating on Thursday morning as it retreats from a rally yesterday.</li>



<li>WiMi Hologram Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/wimi-stock-quote/">WIMI</a>) stock is dropping close to 12% after an unexpected rally yesterday.</li>



<li>Beyond Meat (NASDAQ:<a href="https://investorplace.com/stock-quotes/bynd-stock-quote/">BYND</a>) shares are falling more than 11% on <a href="https://www.wsj.com/articles/beyond-meat-engages-bondholders-for-restructuring-talks-7de6b8ae">restructuring talks with bondholders</a>.</li>



<li>American Rebel (NASDAQ:<a href="https://investorplace.com/stock-quotes/areb-stock-quote/">AREB</a>) stock is decreasing over 11% this morning after rallying on Wednesday.</li>



<li>Aditxt (NASDAQ:<a href="https://investorplace.com/stock-quotes/adtx-stock-quote/">ADTX</a>) shares are slipping more than 10% <a href="https://investorplace.com/2024/07/why-is-aditxt-adtx-stock-up-72-today/">following a rally yesterday</a>.</li>



<li>Stardust Power (NASDAQ:<a href="https://investorplace.com/stock-quotes/sdst-stock-quote/">SDST</a>) stock is dipping over 10% <a href="https://investorplace.com/2024/07/stardust-power-sdst-stock-pops-140-days-after-debut-what-to-know/">after a surprise rally yesterday</a>.</li>



<li>GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) shares close out our pre-market stock movers down more than 9%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-july-18th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Bionomics (BNOX – Research Report), retaining the price target of $8.00. Jos...

Buy Rating Affirmed on Bionomics as BNC210 Enters Critical Phase 3 Trial for Social Anxiety Disorder

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Friday as we check out all of the latest stories affecting shares on the last day of trading this week!



Moving stocks this morning are a Maui fire settlement report, a reverse stock split notice, earnings reports and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Serve Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/serv-stock-quote/">SERV</a>) stock is rocketing more than 68% with heavy trading after announcing <a href="https://www.nasdaq.com/press-release/presentation-times-and-schedule-participating-companies-now-posted-conference-website">a presentation yesterday</a>.</li>



<li>60 Degrees (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/">SXTP</a>) shares are soaring over 37% alongside strong early morning trading.</li>



<li>Hawaiian Electric Industries (NYSE:<a href="https://investorplace.com/stock-quotes/he-stock-quote/">HE</a>) stock is surging more than 37% on reports it included in the <a href="https://finance.yahoo.com/news/hawaiian-electric-among-firms-4-212211492.html">Maui fire settlement</a>.</li>



<li>Power REIT (NYSEMKT:<a href="https://investorplace.com/stock-quotes/pw-stock-quote/">PW</a>) shares are increasing over 23% without any apparent news.</li>



<li>Safe &amp; Green Development (NASDAQ:<a href="https://investorplace.com/stock-quotes/sgd-stock-quote/">SGD</a>) stock is gaining more than 23% with strong pre-market trading.</li>



<li>Novo Integrated Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvos-stock-quote/">NVOS</a>) shares are rising over 22% on a <a href="https://www.businesswire.com/news/home/20240718621664/en/Novo-Integrated-Sciences-Receives-Commencement-of-Disbursement-Notice-for-SBLC-Leasing-and-Monetizing-Program">disbursement funds notice</a>.</li>



<li>Unicycive Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/uncy-stock-quote/">UNCY</a>) stock is climbing more than 15% despite a lack of news this morning.</li>



<li>Talphera (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlph-stock-quote/">TLPH</a>) shares are heading over 13% higher without any clear news to report.</li>



<li>TuanChe (NASDAQ:<a href="https://investorplace.com/stock-quotes/tc-stock-quote/">TC</a>) stock is jumping close to 13% on Friday morning.</li>



<li>Sobr Safe (NASDAQ:<a href="https://investorplace.com/stock-quotes/sobr-stock-quote/">SOBR</a>) shares are up more than 12% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Nauticus Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kitt-stock-quote/">KITT</a>) stock is diving over 19% after <a href="https://www.prnewswire.com/news-releases/nauticus-robotics-announces-transformative-1-for-36-reverse-stock-split-302201004.html">announcing a reverse stock split</a>.</li>



<li>SunPower (NASDAQ:<a href="https://investorplace.com/stock-quotes/spwr-stock-quote/">SPWR</a>) shares are tumbling more than 17% after <a href="https://finance.yahoo.com/news/sunpower-plunges-halting-solar-installs-180816388.html">halting some of its operations</a>.</li>



<li>WaveDancer (NASDAQ:<a href="https://investorplace.com/stock-quotes/wavd-stock-quote/">WAVD</a>) stock is taking a nearly 14% beating on Friday morning.</li>



<li>CrowdStrike (NASDAQ:<a href="https://investorplace.com/stock-quotes/crwd-stock-quote/">CRWD</a>) shares are sliding over 13% <a href="https://www.cnbc.com/2024/07/19/crowdstrike-suffers-major-outage-affecting-businesses-around-the-world.html">alongside outages and issues</a>.</li>



<li>Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) stock is dropping more than 11% <a href="https://www.nasdaq.com/press-release/bionomics-initiates-affirm-1-phase-3-clinical-trial-bnc210-social-anxiety-disorder">following clinical trial results yesterday</a>.</li>



<li>Scholastic (NASDAQ:<a href="https://investorplace.com/stock-quotes/schl-stock-quote/">SCHL</a>) shares are decreasing over 11% with its <a href="https://www.benzinga.com/news/earnings/24/07/39849856/scholastic-shares-fall-after-worse-than-expected-q4-results-details">fiscal Q4 earnings report</a>.</li>



<li>Salarius Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/slrx-stock-quote/">SLRX</a>) stock is falling more than 10% after a major rally yesterday.</li>



<li>HighPeak Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/hpkew-stock-quote/">HPKEW</a>) shares are slipping over 10% this morning.</li>



<li>Super League Enterprise (NASDAQ:<a href="https://investorplace.com/stock-quotes/sle-stock-quote/">SLE</a>) stock is dipping almost 10% today.</li>



<li>CytoMed Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/gdtc-stock-quote/">GDTC</a>) shares are down more than 9%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-july-19th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news happening this morning!



Moving stocks this morning are clinical trial updates, earnings reports and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Primech (NASDAQ:<a href="https://investorplace.com/stock-quotes/pmec-stock-quote/">PMEC</a>) stock is rocketing close to 90% alongside heavy pre-market trading.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) shares are soaring more than 69% with strong early morning trading.</li>



<li>Heramba Electric (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PITA#NASDAQ">PITA</a>) stock is surging over 43% with increasing trading activity this morning.</li>



<li>Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) shares are gaining more than 31% on a <a href="https://www.nasdaq.com/press-release/bionomics-announces-successful-end-phase-2-meeting-fda-development-bnc210-post">Phase 2 clinical trial meeting</a>.</li>



<li>Powell Industries (NASDAQ:<a href="https://investorplace.com/stock-quotes/powl-stock-quote/">POWL</a>) stock is rising over 25% after <a href="https://finance.yahoo.com/news/powell-industries-powl-q3-earnings-214005995.html">beating Q3 estimates</a>.</li>



<li>BIMI International Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/bimi-stock-quote/">BIMI</a>) shares are increasing more than 20% with strong early morning trading today.</li>



<li>DallasNews (NASDAQ:<a href="https://investorplace.com/stock-quotes/daln-stock-quote/">DALN</a>) stock is climbing over 18% with its <a href="https://investorplace.com/earning-results/2024/07/daln-stock-earnings-dallasnews-for-q2-of-2024/">Q2 earnings report</a>.</li>



<li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) shares are jumping more than 17% after <a href="https://finance.yahoo.com/news/faraday-future-regains-compliance-nasdaq-031500213.html">regaining listing compliance</a>.</li>



<li>GraniteShares 2x Long AMD Daily ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/amdl-stock-quote/">AMDL</a>) stock is getting an over 17% boost this morning.</li>



<li>Talen Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/tln-stock-quote/">TLN</a>) shares are up more than 17% after <a href="https://www.nasdaq.com/press-release/talen-reports-pjm-auction-results-2025-2026-planning-year-2024-07-30">reporting PJM Auction Results</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>FibroGen (NASDAQ:<a href="https://investorplace.com/stock-quotes/fgen-stock-quote/">FGEN</a>) stock is plummeting over 44% on a <a href="https://www.nasdaq.com/press-release/fibrogen-announces-topline-results-two-late-stage-pamrevlumab-pancreatic-cancer">failed clinical trial</a>.</li>



<li>Macrogenics (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgnx-stock-quote/">MGNX</a>) shares are diving more than 26% as it <a href="https://www.nasdaq.com/press-release/macrogenics-provides-vobramitamab-duocarmazine-update-2024-07-30">discontinues a clinical trial</a>.</li>



<li>Jet AI (NASDAQ:<a href="https://investorplace.com/stock-quotes/jtai-stock-quote/">JTAI</a>) stock is tumbling over 21% on an <a href="https://www.nasdaq.com/press-release/jetai-announces-expiration-and-successful-results-exchange-offer-and-consent">exchange offer for its warrants</a>.</li>



<li>Penumbra (NYSE:<a href="https://investorplace.com/stock-quotes/pen-stock-quote/">PEN</a>) shares are taking a more than 18% beating <a href="https://finance.yahoo.com/news/penumbra-pen-reports-q2-earnings-230019255.html">with its Q2 earnings report</a>.</li>



<li>Groupon (NASDAQ:<a href="https://investorplace.com/stock-quotes/grpn-stock-quote/">GRPN</a>) stock is sliding over 17% <a href="https://investorplace.com/earning-results/2024/07/grpn-stock-earnings-groupon-for-q2-of-2024/">on an EPS miss</a>.</li>



<li>Definitive Healthcare (NASDAQ:<a href="https://investorplace.com/stock-quotes/dh-stock-quote/">DH</a>) shares are falling more than 16% without any clear news this morning.</li>



<li>Netcapital (NASDAQ:<a href="https://investorplace.com/stock-quotes/ncpl-stock-quote/">NCPL</a>) stock is dropping over 16% after <a href="https://investorplace.com/earning-results/2024/07/ncpl-stock-earnings-netcapital-for-q4-of-2024/">missing estimates in fiscal 2024</a>.</li>



<li>O-I Glass (NYSE:<a href="https://investorplace.com/stock-quotes/oi-stock-quote/">OI</a>) shares are decreasing more than 15% <a href="https://www.stocktitan.net/news/OI/o-i-glass-reports-second-quarter-2024-71rm58wp8yg0.html">with its Q2 results</a>.</li>



<li>Lemonade (NYSE:<a href="https://investorplace.com/stock-quotes/lmnd-stock-quote/">LMND</a>) stock is slipping over 13% <a href="https://www.marketwatch.com/story/lemonades-stock-slides-14-after-posting-q2-loss-5e14bea8">alongside a weak guidance</a>.</li>



<li>Tivic Health Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/tivc-stock-quote/">TIVC</a>) shares close out our pre-market stock movers down 13% <a href="https://investorplace.com/2024/07/tivic-health-systems-tivc-stock-pops-another-39-july-29th/">after a rally yesterday</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-july-31st/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Bionomics (BNOX – Research Report) today and set a price target of $8.00. Josep...

Bionomics Poised for Phase 3 Success with BNC210 Following Favorable FDA Meeting: A Strong Buy Recommendation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are a hot topic on Wednesday and we have all of the biggest stories traders need to know about this morning!



Moving stocks this morning are earnings reports, a stock offering, a reverse stock split and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Digital Ally (NASDAQ:<a href="https://investorplace.com/stock-quotes/dgly-stock-quote/">DGLY</a>) stock is rocketing more than 107% alongside heavy pre-market trading.</li>



<li>Viracta Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/virx-stock-quote/">VIRX</a>) shares are soaring over 53% with the <a href="https://www.nasdaq.com/press-release/viracta-therapeutics-reports-second-quarter-2024-financial-results-and-provides">release of its Q2 earnings report</a>.</li>



<li>Conduit Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdt-stock-quote/">CDT</a>) stock is surging more than 42% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318518494&amp;type=PDF&amp;symbol=CDT&amp;cdn=197541151657f71d6ed19abcc1e0e48e&amp;companyName=Conduit+Pharmaceuticals+Inc.&amp;formType=3&amp;formDescription=Initial+statement+of+beneficial+ownership+of+securities&amp;dateFiled=2024-08-13">an investment update</a>.</li>



<li>Nuburu (NYSEMKT:<a href="https://investorplace.com/stock-quotes/buru-stock-quote/">BURU</a>) shares are rising over 26% despite a lack of news this morning.</li>



<li>Jianzhi Education Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/jz-stock-quote/">JZ</a>) stock is gaining close to 19% even with a <a href="https://www.nasdaq.com/press-release/jianzhi-education-technology-group-company-limited-receives-nasdaq-notification-0">recent delisting notice</a>.</li>



<li>Edible Garden (NASDAQ:<a href="https://investorplace.com/stock-quotes/edbl-stock-quote/">EDBL</a>) shares are increasing more than 18% on <a href="https://www.nasdaq.com/press-release/edible-garden-reports-157-increase-gross-profit-fueled-year-over-year-growth-61-cut">strong Q2 earnings</a>.</li>



<li>Ucloudlink (NASDAQ:<a href="https://investorplace.com/stock-quotes/ucl-stock-quote/">UCL</a>) stock is heading over 16% higher with its <a href="https://www.nasdaq.com/press-release/ucloudlink-group-inc-announces-unaudited-second-quarter-2024-financial-results-2024">most recent earnings report</a>.</li>



<li>Vertex Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtnr-stock-quote/">VTNR</a>) shares are jumping 16% with strong early morning trading.</li>



<li>Serve Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/serv-stock-quote/">SERV</a>) stock is climbing more than 15% with its <a href="https://www.stocktitan.net/news/SERV/serve-robotics-announces-second-quarter-2024-wqwtqr037uv4.html">Q2 earnings report</a>.</li>



<li>Kamada (NASDAQ:<a href="https://investorplace.com/stock-quotes/kmda-stock-quote/">KMDA</a>) shares are up over 15% after posting <a href="https://www.nasdaq.com/press-release/kamada-reports-strong-second-quarter-and-first-half-2024-financial-results-year-over">positive Q2 earnings results</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>TC BioPharm (NASDAQ:<a href="https://investorplace.com/stock-quotes/tcbp-stock-quote/">TCBP</a>) stock is crashing more than 42% after <a href="https://www.nasdaq.com/press-release/tc-biopharm-announces-pricing-20-registered-direct-offering-2024-08-13">pricing a registered direct offering</a>.</li>



<li>Surgepays (NASDAQ:<a href="https://investorplace.com/stock-quotes/surg-stock-quote/">SURG</a>) shares are plummeting over 26% after <a href="https://www.prnewswire.com/news-releases/surgepays-announces-second-quarter-2024-financial-results-302221503.html">reporting a Q2 loss</a>.</li>



<li>Arcadia Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/rkda-stock-quote/">RKDA</a>) stock is diving more than 16% after <a href="https://markets.businessinsider.com/news/stocks/rkda-stock-earnings-arcadia-biosciences-for-q2-of-2024-1033684150">missing Q2 EPS estimates</a>.</li>



<li>Ouster (NYSE:<a href="https://investorplace.com/stock-quotes/oust-stock-quote/">OUST</a>) shares are taking an over 16% beating on <a href="https://www.businesswire.com/news/home/20240813944318/en/Ouster-Reports-Strong-Revenue-and-Margins-for-Second-Quarter-2024">mixed Q2 earnings</a>.</li>



<li>QuickLogic (NASDAQ:<a href="https://investorplace.com/stock-quotes/quik-stock-quote/">QUIK</a>) stock is tumbling more than 16% with its <a href="https://www.prnewswire.com/news-releases/quicklogic-reports-41-year-over-year-revenue-growth-for-second-quarter-fiscal-2024-302221555.html">latest earnings release</a>.</li>



<li>Brinker International (NYSE:<a href="https://investorplace.com/stock-quotes/eat-stock-quote/">EAT</a>) shares are sliding over 16% after <a href="https://www.investing.com/news/stock-market-news/brinker-international-stock-tumbles-13-on-q4-earnings-miss-93CH-3570960">posting an earnings miss</a>.</li>



<li>Portage Biotech (NASDAQ:<a href="https://investorplace.com/stock-quotes/prtg-stock-quote/">PRTG</a>) stock is falling more than 15% after <a href="https://www.stocktitan.net/news/PRTG/portage-biotech-announces-1-for-20-reverse-stock-sficaewojjpr.html">announcing a reverse stock split</a>.</li>



<li>Global E Online (NASDAQ:<a href="https://investorplace.com/stock-quotes/glbe-stock-quote/">GLBE</a>) shares are decreasing over 14% with its <a href="https://www.stocktitan.net/news/GLBE/global-e-reports-second-quarter-2024-1dq5hcfetvn1.html">Q2 earnings report</a>.</li>



<li>Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) stock is dropping more than 14% without any clear news this morning.</li>



<li>WISeKey (NASDAQ:<a href="https://investorplace.com/stock-quotes/wkey-stock-quote/">WKEY</a>) shares close out our pre-market stock movers down nearly 14% on a <a href="https://www.nasdaq.com/press-release/sealcoin-secures-50-million-investment-commitment-gem-digital-limited-through-0">new investment</a> <a href="https://www.nasdaq.com/press-release/wisekey-partners-venafi-post-quantum-encryption-services-2024-08-14">and partnership</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/2024/08/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-aug-14th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ADTX

AMDL

APLM

APVO

AREB

BANL

BIMI

BNOX

BURU

BYND

CHUY

CRWD

DALN

DGLY

EDBL

FFIE

FGEN

GDTC

GLBE

GRPN

HPKEW

JTAI

KITT

KMDA

LESL

LMND

MGNX

NCPL

NUZE

NVOS

ONCO

OUST

PITA

PMEC

POWL

PRTG

QUIK

RKDA

SCHL

SDST

SERV

SLRX

SOBR

SPWR

SURG

SXTP

TCBP

TIVC

TLPH

UNCY

VIRX

VTNR

WAVD

WIMI

WKEY

XWEL

ZIMV

Press Releases

Bionomics Provides a Review of 2023 and of 2024 Plans

Small-Cap Nasdaq Stocks to Watch Now! VTAK, BNOX, INBS, DYAI, KAVL

Bionomics to Present at the 2024 BIO CEO & Investor Conference

Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder

Health Care

Bionomics to Present at the 2024 American Society of Clinical Psychopharmacology Annual Meeting

Bionomics Limited Announces Private Placement of up to $70.0 Million

Bionomics Initiates AFFIRM-1, a Phase 3 Clinical Trial with BNC210 for Social Anxiety Disorder

Bionomics to Provide a Corporate Update and Discuss End-of-Phase 2 Meeting Outcomes on the Development of BNC210 in PTSD on July 31, 2024

Bionomics Announces Successful End-of-Phase 2 Meeting with the FDA on the Development of BNC210 in Post-Traumatic Stress Disorder

Bionomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Comments

Bionomics

Interés en corto

Bionomics (NASDAQ:BNOX) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL